Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 16th Preview)
-
FDA approves ctDNA MRD-guided Tecentriq in bladder cancer, with Natera CDx
The FDA on Friday approved Genentech’s Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for muscle-invasive bladder cancer patients with circulating tumor DNA after cystectomy, as determined by Natera’s Signatera MRD assay. The approval makes this the first ctDNA MRD-guided regulatory decision in bladder cancer. In the Phase III IMvigor011 trial, 250 MIBC patients who were ctDNA-positive on Signatera after cystectomy but had no radiographic disease were randomized to Tecentriq versus placebo. Disease-free survival was nearly doubled with Tecentriq (9.9 months vs 4.8 months), and median overall survival improved (32.8 months vs 21.1 months). Genentech and Natera also highlighted that Signatera received simultaneous FDA authorization as a companion diagnostic to identify patients likely to benefit, marking the first time the FDA cleared a blood-based MRD assay as a CDx. For clinicians, the label also frames a potential treatment-de-escalation pathway for ctDNA-negative patients by supporting safer omission of adjuvant immunotherapy following cystectomy.
-
Aardvark Therapeutics hit with full FDA clinical hold for Prader-Willi drug
Aardvark Therapeutics said the FDA has placed a full clinical hold on all tests of its Prader-Willi syndrome program, halting activity after a cardiovascular safety signal emerged earlier in healthy-volunteer dosing at higher than intended exposures. The hold stops trials involving ARD-101, the company’s small-molecule metabolic therapy designed to address hyperphagia. Aardvark plans to unblind data from a Phase 3 trial and an open-label extension to help regulators evaluate the totality of efficacy and safety signals and determine next steps. The company reported it has dosed 68 participants in the placebo-controlled Phase 3 study and 19 in the open-label extension. The hold compounds a tight execution and financing timeline. With cash run-rate expectations previously mapped to mid-2027, unblinding and any FDA-agreed pathway will likely need to be completed quickly to preserve patient access and support fundraising. The affected regulatory decision also positions competitors around Vyktat (soleno Therapeutics) as the existing approved option for PWS hyperphagia, increasing scrutiny on whether ARD-101’s risk-benefit can be redesigned under FDA dosing expectations.
-
Regenxbio’s Duchenne gene therapy clears pivotal bar, aims for FDA submission
Regenxbio reported that its Duchenne muscular dystrophy gene therapy met the primary bar in a pivotal study, generating a roadmap toward an FDA submission. The result centers on sufficiently high levels of a miniaturized dystrophin protein produced by its RGX-202 platform, which is intended as a potentially safer alternative to therapies that have faced liver-related safety concerns. Multiple reports tied the milestone to high functional and molecular activity in patients from the pivotal portion of the program. The company positioned the data as supportive of accelerated approval discussions, while also signaling an application timing aligned with a continued development path. In market terms, the update follows recent turbulence for Regenxbio tied to earlier regulatory and safety uncertainty. The pivotal readout is expected to reframe investor expectations around the likelihood of a near-term FDA interaction. For the field, the announcement reinforces that gene therapy durability and protein expression are once again becoming key decision points in DMD late-stage regulatory planning.
-
Create Medicines closes $122M Series B to scale in vivo CAR-T pipeline
Create Medicines raised $122 million in a Series B financing to advance its in vivo CAR-T platform across autoimmune disease and oncology. The company, formerly known as Myeloid Therapeutics, uses an mRNA-LNP approach designed to reprogram immune cells inside the body with a goal of enabling repeat dosing and eliminating the ex vivo manufacturing bottleneck. The funding co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners supported a pipeline that includes CRT-402, a CD19-targeted in vivo CAR-T for autoimmune indications, and an additional program targeting CD19 and BCMA. In oncology, Create is pushing MT-303 in hepatocellular carcinoma following early responses. Create disclosed that it has dosed more than 50 patients across its clinical programs, and the company framed the capital raise as runway extension rather than a reset, emphasizing continued internal manufacturing investment. The proceeds are also intended to keep clinical execution and data generation the central priority. The deal underscores sustained investor appetite for cellular therapies that can be delivered with shorter, scalable “one-day” manufacturing cycles—particularly in autoimmune disease where repeated immune modulation may broaden the therapeutic window.
-
Isomorphic Labs secures massive $2.1B Series B to scale AI drug discovery
Isomorphic Labs, the Google-backed AI drug discovery company, secured a $2.1 billion Series B round as it looks to scale its AI drug design engine and move therapeutic programs closer to clinical development. The financing was led by Thrive Capital and included participation from existing and new investors. The company described its underlying system, IsoDDE, as an integrated drug design and development engine rather than a software product to be licensed. It said proceeds will support continued scaling of model development, pipeline advancement, and hiring across AI, engineering, drug design, and clinical development. Isomorphic emphasized an internal therapeutic focus on oncology and immunology while keeping the longer-term model capability broad. The company also reiterated existing partnerships with major pharma collaborators, indicating the funding is aimed at both platform scale and translation. For the biotech industry, the round signals that large-scale capital continues to reward AI-first approaches—particularly those that can demonstrate productivity from model outputs into real development plans.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.